Skip to main navigation Skip to search Skip to main content

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

  • Christopher P. Cannon (Lead / Corresponding author)
  • , Bertrand Cariou
  • , Dirk Blom
  • , James M. McKenney
  • , Christelle Lorenzato
  • , Robert Pordy
  • , Umesh Chaudhari
  • , Helen M. Colhoun
  • , for the ODYSSEY COMBO II Investigators

    Research output: Contribution to journal › Article › peer-review

    379   Link opens in a new tab Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial'. Together they form a unique fingerprint.
    Sort by

    Keyphrases

    Pharmacology, Toxicology and Pharmaceutical Science